Prostate Cancer Cell Line (22Rv1-undup1)

Human prostate cancer cell line, 22Rv1-undup1 is one of the clones isolated from 22Rv1 that is genetically corrected using TAL effector nuclease to delete the tandem duplication of 2b-exon3-CE1-3 of androgen receptor genome in 22Rv1 cell that drives the expression of androgen receptor variant 7 (ARv7).

Highlights:

  • Expresses ARv7
  • ARvs level is significantly reduced by this AR genomic correction

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. The androgen receptor (AR) helps prostate cancer cells to survive and is a target for many anti cancer research studies by looking at inhibition.

From the laboratory of Scott S. Dehm, PhD, University of Minnesota, Twin Cities.

Catalog Number Product Size AVAILABILITY Price Qty
EMN025-FP
Prostate Cancer Cell Line (22Rv1-undup1)
1 vial 3-5 weeks
Regular Price:$499.00

This product is for sale to Nonprofit customers only. For profit customers, please Contact Us for more information.

Specifications

Product Type: Cell Line
Name: 22Rv1-undup1
Cell Type: Prostate Cancer
Organism: Human
Morphology: Epithelial cells
Source: Prostate
Biosafety Level: BSL 2
Growth Conditions: RPMI Medium 1640 - L-Glutamine (Invitrogen 11875), 10% FBS, 1xPen/Strep
Subculturing: Seed 22Rv1-undup1 cell at 1X106/T75 flask, change medium twice a week and split 1 to 4 splitting once to twice a week
Cryopreservation: RPMI1640 , 20 % FBS and 10 %DMSO
Storage: Liquid nitrogen
Shipped: Dry Ice

Provider
From the laboratory of Scott M. Dehm, PhD, University of Minnesota, Twin Cities.
References
  1. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res. 2011;71(6):2108–2117. doi:10.1158/0008-5472.CAN-10-1998.
  2. Van Etten JL, Nyquist M, Li Y, et al. Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer. Cancer Res. 2017;77(19):5228–5235. doi:10.1158/0008-5472.CAN-17-0320.

If you publish research with this product, please let us know so we can cite your paper.

Loading...